Clinical Trials Browser

Phase 2/3 × Interventional × Melanoma × Clear all

NCT02339571 2026-03-17

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

Melanoma

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

Phase 2/3 Recruiting

BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT01861938 2025-10-02

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Phase 2/3 Withdrawn

Melanoma, Neoplasm Metastasis

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

Melanoma

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Melanoma

NCT04901988 2025-02-27

DETECTION

Phase 2/3 Terminated

Melanoma

NCT01088737 2019-08-13

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Phase 2/3 Unknown

Melanoma, Hutchinson's Melanotic Freckle

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Phase 2/3 Terminated

126 enrolled 9 charts

Melanoma

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2/3 Completed

9 enrolled 7 charts

DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02962947 2016-11-15

MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients

Phase 2/3 Unknown

Melanoma

NCT00811200 2009-07-02

TORR

Phase 2/3 Unknown

Uveal Melanoma, Macular Degeneration, Melanoma, Retinal Diseases, Choroid Diseases

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2/3 Completed

Melanoma, Neoplasm Metastasis